

# Karen S Anderson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4249002/publications.pdf>

Version: 2024-02-01

67  
papers

5,002  
citations

136950

32  
h-index

110387

64  
g-index

68  
all docs

68  
docs citations

68  
times ranked

8706  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Solvent selective membrane routing and microfluidic architecture towards centrifugal automation of customisable bead based immunoassays. <i>Sensors and Actuators B: Chemical</i> , 2022, 356, 131305.                    | 7.8  | 8         |
| 2  | Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2410, 649-670.  | 0.9  | 11        |
| 3  | The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II and metastatic breast cancers. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 65-78. | 2.5  | 10        |
| 4  | Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 751-761.   | 2.4  | 4         |
| 5  | Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. <i>BMJ, The</i> , 2021, 373, n1087.  | 6.0  | 59        |
| 6  | Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. <i>Oral Oncology</i> , 2021, 120, 105397.   | 1.5  | 11        |
| 7  | Safety and feasibility of intrathecal pembrolizumab infusion in refractory triple negative breast cancer with leptomeningeal disease: A case report. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100103.    | 0.1  | 0         |
| 8  | Autoantibodies in Early Detection of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2475-2485.   | 2.5  | 16        |
| 9  | Biomarkers and Strategies for Early Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2504-2512.  | 2.5  | 53        |
| 10 | Unique genomic and neoepitope landscapes across tumors: a study across time, tissues, and space within a single lynch syndrome patient. <i>Scientific Reports</i> , 2020, 10, 12190.                                      | 3.3  | 3         |
| 11 | Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. <i>Nature Communications</i> , 2019, 10, 1842.  | 12.8 | 126       |
| 12 | The neoepitope landscape of breast cancer: implications for immunotherapy. <i>BMC Cancer</i> , 2019, 19, 200.   | 2.6  | 68        |
| 13 | Weakly immunogenic CRISPR therapies. <i>Nature Biomedical Engineering</i> , 2019, 3, 761-762.   | 22.5 | 2         |
| 14 | A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment. <i>Clinical Cancer Research</i> , 2019, 25, 142-149.                   | 7.0  | 16        |
| 15 | HPV: Immunology lessons from an ancient oncotarget. <i>Oncotarget</i> , 2019, 10, 1269-1270.  | 1.8  | 4         |
| 16 | Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. <i>International Journal of Cancer</i> , 2018, 143, 515-526.   | 5.1  | 18        |
| 17 | An Automated Microfluidic Assay for Photonic Crystal Enhanced Detection and Analysis of an Antiviral Antibody Cancer Biomarker in Serum. <i>IEEE Sensors Journal</i> , 2018, 18, 1464-1473.                               | 4.7  | 5         |
| 18 | Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer: Methodologic issues. <i>Oral Oncology</i> , 2018, 80, 93.   | 1.5  | 1         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Modeling the Subclonal Evolution of Cancer Cell Populations. <i>Cancer Research</i> , 2018, 78, 830-839.  | 0.9  | 37        |
| 20 | Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy. <i>Expert Review of Proteomics</i> , 2018, 15, 1065-1077.   | 3.0  | 12        |
| 21 | Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer. <i>Cancer Research</i> , 2018, 78, 6159-6170.  | 0.9  | 61        |
| 22 | JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1205-e1215.   | 2.4  | 46        |
| 23 | Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, $\beta$ 1-4 Branching, $\beta$ 1-6 Branching, and $\beta$ 2-6 Sialylation in Cancer. <i>Journal of Proteome Research</i> , 2018, 17, 3.7 543-558.         |      | 19        |
| 24 | Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. <i>Cancer Biomarkers</i> , 2017, 19, 129-136.  | 1.7  | 22        |
| 25 | Autoantibody biomarkers for the detection of serous ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 129-136.   | 1.4  | 53        |
| 26 | Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies. <i>Scientific Reports</i> , 2017, 7, 3322.  | 3.3  | 26        |
| 27 | Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer. <i>Oral Oncology</i> , 2017, 73, 132-137.   | 1.5  | 10        |
| 28 | Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. <i>Cancer</i> , 2017, 123, 4886-4894.   | 4.1  | 16        |
| 29 | Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. <i>Modern Pathology</i> , 2017, 30, 1516-1526. | 5.5  | 22        |
| 30 | Serum Immune Profiling for Early Detection of Cervical Disease. <i>Theranostics</i> , 2017, 7, 3814-3823.   | 10.0 | 17        |
| 31 | Programmable protein arrays for immunoprofiling HPV-associated cancers. <i>Proteomics</i> , 2016, 16, 1215-1224.  | 2.2  | 14        |
| 32 | Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. <i>Proteomics - Clinical Applications</i> , 2016, 10, 720-731.  | 1.6  | 26        |
| 33 | Application of flat panel OLED display technology for the point-of-care detection of circulating cancer biomarkers. <i>Scientific Reports</i> , 2016, 6, 29057.   | 3.3  | 29        |
| 34 | T-Cell Epitope Discovery for Therapeutic Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2016, 1403, 779-796.  | 0.9  | 11        |
| 35 | Proteomic Monitoring of B Cell Immunity. <i>Methods in Molecular Biology</i> , 2016, 1403, 131-152.   | 0.9  | 3         |
| 36 | Crucial considerations for pipelines to validate circulating biomarkers for breast cancer. <i>Expert Review of Proteomics</i> , 2016, 13, 201-211.  | 3.0  | 6         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. <i>Oral Oncology</i> , 2015, 51, 662-667.  | 1.5 | 51        |
| 38 | Plasma Autoantibodies Associated with Basal-like Breast Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1332-1340.  | 2.5 | 42        |
| 39 | Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 435-441.                             | 2.5 | 13        |
| 40 | Modelling the effect of early detection of Ebola. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 148-149.   | 9.1 | 46        |
| 41 | Immunotherapy for the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2015, 17, 5.  | 4.0 | 59        |
| 42 | HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. <i>Clinical Cancer Research</i> , 2015, 21, 2861-2869.          | 7.0 | 59        |
| 43 | Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. <i>Oral Oncology</i> , 2015, 51, 751-758.   | 1.5 | 34        |
| 44 | TCR contact residue hydrophobicity is a hallmark of immunogenic CD8 <sup>+</sup> T cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1754-62. | 7.1 | 200       |
| 45 | Autoantibody Signature for the Serologic Detection of Ovarian Cancer. <i>Journal of Proteome Research</i> , 2015, 14, 578-586.  | 3.7 | 90        |
| 46 | Genomic amplification of 9p24.1 targeting <i>JAK2</i> , <i>PD-L1</i> , and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 26483-26493.                       | 1.8 | 118       |
| 47 | Oral Human Papillomavirus (HPV) Infection in HPV-Positive Patients With Oropharyngeal Cancer and Their Partners. <i>Journal of Clinical Oncology</i> , 2014, 32, 2408-2415.                                     | 1.6 | 139       |
| 48 | Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens. <i>Immunobiology</i> , 2014, 219, 583-592.             | 1.9 | 25        |
| 49 | A versatile protein microarray platform enabling antibody profiling against denatured proteins. <i>Proteomics - Clinical Applications</i> , 2013, 7, 378-383.   | 1.6 | 34        |
| 50 | Autoantibodies and Biomarker Discovery. , 2013, , 363-378.  |     | 1         |
| 51 | Biomarker Discovery for Heterogeneous Diseases. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 747-755.   | 2.5 | 49        |
| 52 | Protein Microarray Signature of Autoantibody Biomarkers for the Early Detection of Breast Cancer. <i>Journal of Proteome Research</i> , 2011, 10, 85-96.  | 3.7 | 197       |
| 53 | Multiplexed Detection of Antibodies Using Programmable Bead Arrays. <i>Methods in Molecular Biology</i> , 2011, 723, 227-238.   | 0.9 | 13        |
| 54 | Autoantibodies in cancer: prognostic biomarkers and immune activation. <i>Expert Review of Proteomics</i> , 2011, 8, 577-589.   | 3.0 | 32        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 857-867.   | 4.2  | 10        |
| 56 | The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24 <sup>low</sup> stem cell <sup>like</sup> breast cancer cells in human tumors. <i>Journal of Clinical Investigation</i> , 2011, 121, 2723-2735.   | 8.2  | 777       |
| 57 | p53 Autoantibodies as Potential Detection and Prognostic Biomarkers in Serous Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 859-868.   | 2.5  | 95        |
| 58 | A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on Human Papillomavirus 16-transformed HLA-A2+ Epithelial Cancers. <i>Journal of Biological Chemistry</i> , 2010, 285, 29608-29622.   | 3.4  | 71        |
| 59 | Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. <i>Journal of Immunological Methods</i> , 2009, 350, 171-182.  | 1.4  | 58        |
| 60 | Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: Prolonged survival. <i>Vaccine</i> , 2009, 27, 1825-1833.   | 3.8  | 17        |
| 61 | Tumor Vaccines for Breast Cancer. <i>Cancer Investigation</i> , 2009, 27, 361-368.  | 1.3  | 36        |
| 62 | Tracking humoral responses using self assembling protein microarrays. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1518-1527.   | 1.6  | 39        |
| 63 | Application of Protein Microarrays for Multiplexed Detection of Antibodies to Tumor Antigens in Breast Cancer. <i>Journal of Proteome Research</i> , 2008, 7, 1490-1499.  | 3.7  | 140       |
| 64 | Molecular Definition of Breast Tumor Heterogeneity. <i>Cancer Cell</i> , 2007, 11, 259-273.   | 16.8 | 1,273     |
| 65 | Phase I/II Combined Chemoimmunotherapy with Carcinoembryonic Antigen <sup>Derived</sup> HLA-A2 <sup>Restricted</sup> CAP-1 Peptide and Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Primary Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5993-6001. | 7.0  | 62        |
| 66 | The Sentinel Within: Exploiting the Immune System for Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2005, 4, 1123-1133.  | 3.7  | 297       |
| 67 | The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. <i>Blood</i> , 2003, 102, 3287-3294.   | 1.4  | 77        |